Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1911124 | 1.00 | SHBG (0.41) | SHBGEPHX1NPSR1CA12CA1 | |
| SCHEMBL13002271 | 0.98 | SHBG (0.37) | SHBGEPHX1NPSR1CA12CA1 | |
| SCHEMBL12722105 | 0.87 | — | — | |
| SCHEMBL14407171 | 0.87 | — | — | |
| SCHEMBL11042843 | 0.83 | SHBG (0.42) | SHBGEPHX1CA12CA1CA2 | |
| SCHEMBL2354256 | 0.83 | SHBG (0.42) | SHBGEPHX1TP53LMNASMN1; SMN2 | |
| SCHEMBL5678824 | 0.83 | MME (0.33) | SHBGCA12CA1CA2MMP2 | |
| SCHEMBL12857262 | 0.82 | SHBG (0.38) | SHBGEPHX1CA12CA1CA2 | |
| SCHEMBL10136483 | 0.81 | SHBG (0.41) | SHBGEPHX1TP53LMNASMN1; SMN2 | |
| SCHEMBL1925159 | 0.78 | SHBG (0.54) | SHBGEPHX1NPSR1TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3066637-A | — | — | None | — | — | JP | disclosed |
| US-8445527-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| US-7846587-B2 | noncrystalline fluorine containing polyethers; perfluoropolyethers; high molecular weight, high ionic conductivity at room temperature, low viscosity, nonflammable, oxidation resistance; for use as electrolyte of lithium secondary batteries, capacitors, and solar cells | DAIKIN INDUSTRIES, LTD. (JP) | 2010-12-07 | — | — | US | disclosed |
| US-7595299-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080020275-A1 | noncrystalline fluorine containing polyethers; perfluoropolyethers; high molecular weight, high ionic conductivity at room temperature, low viscosity, nonflammable, oxidation resistance; for use as electrolyte of lithium secondary batteries, capacitors, and solar cells | DAIKIN INDUSTRIES, LTD. (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| JP-H0366637-A | 2-CYCLOHEXYLPROPANOL DERIVATIVE AND PERFUME COMPOSITION CONTAINING THE SAME | KAO CORP | 1991-03-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | SHBG 2253/4885EPHX1 1446/4885NPSR1 2784/4885 |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | SHBG 2253/4885EPHX1 1446/4885NPSR1 2784/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | SHBG 2253/4885EPHX1 1446/4885NPSR1 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.